Regenerative medicine device maker RegenLab USA (RGNA.US) sets IPO price at $6-8 per share, aims to raise $18 million.

RegenLab USA, a medical device company focused on regenerative medicine applications such as tissue repair, announced the terms of its IPO on Tuesday. The Jersey City, New Jersey-based company plans to offer 2.5 million shares at a price of $6 to $8 per share to raise $18 million. At the midpoint of the proposed offering price range, RegenLab USA would have a fully diluted market value of $157 million. RegenLab develops and manufactures single-use devices that prepare autologous platelet-rich plasma (PRP) at the point of care, for use alone or in combination with hyaluronic acid (HA). Its products are used in musculoskeletal, wound care, medical aesthetics, and women's health applications. The company's two main products are the RegenKit PRP preparation kit and Cellular Matrix, a PRP-HA combination product for knee osteoarthritis. Most products have received European CE certification; several RegenKit products, including a wound gel covered by Medicare, have received U.S. FDA approval. Cellular Matrix has not yet been approved in the United States and remains in the PMA (premarket approval) process. The company was founded in Switzerland in 2003, has manufacturing facilities in Switzerland, France, and New Jersey, and sells in approximately 90 countries through a direct sales team and distributors. RegenLab USA was founded in 2003 and generated revenue of $54 million in the 12 months ended June 30, 2026. The company plans to list on Nasdaq under the ticker "RGNA." StoneX Financial is serving as the sole underwriter for the offering.